← Back to Search

Procedure

Focal Laser Ablation for Prostate Cancer

N/A
Recruiting
Research Sponsored by Genesis Research LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial tests a new laser treatment for men with early-stage prostate cancer. The treatment uses ultrasound to guide the laser, making it more precise and safer. The goal is to see if this method is effective and safe, while also preserving sexual and urinary functions. Photodynamic therapy has been studied as a possible treatment for both recurrent and primary prostate cancer.

Who is the study for?
Men aged 40-85 with low-risk or favorable intermediate risk prostate cancer, PSA <20 ng/ml, and clinical tumor stage T2b or less. Candidates must have a lesion visible on micro-ultrasound and MRI, be able to undergo local anesthesia and Nitrous Oxide sedation, have normal rectal anatomy, and lesions not exceeding 50% of the lobe volume.
What is being tested?
The trial tests trans-perineal focal laser ablation (FLA) using the TRANBERG Thermal Therapy System combined with high frequency micro-ultrasound imaging for targeted treatment of localized prostate cancer lesions. It aims to improve safety, efficacy while preserving sexual function and minimizing incontinence.
What are the potential side effects?
Potential side effects may include discomfort at the treatment site, risks associated with local anesthesia or Nitrous Oxide sedation. There's also a possibility of temporary urinary incontinence or changes in sexual function due to proximity to sensitive structures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and Tolerability: Number of Adverse Events Related to the Treatment
Secondary study objectives
Efficacy: Extent of Tumor Ablation by Laser Application

Trial Design

1Treatment groups
Experimental Treatment
Group I: Laser AblationExperimental Treatment1 Intervention
TRANBERG® Transperineal Micro Ultrasound guided laser ablation of Prostate Cancer.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for prostate cancer include radical prostatectomy, radiation therapy (RT), and focal therapies like Trans-perineal Focal Laser Ablation (FLA). Radical prostatectomy involves surgically removing the prostate gland, which directly eliminates the cancerous tissue but can impact urinary and sexual function. Radiation therapy uses high-energy rays to kill cancer cells, which can affect surrounding tissues, leading to bowel and sexual dysfunction. FLA, a focal therapy, uses laser-induced thermal energy to precisely target and destroy cancerous tissue while sparing surrounding structures, potentially preserving urinary and sexual function better than more invasive treatments. Understanding these mechanisms helps patients and doctors choose treatments that balance cancer control with quality of life considerations.

Find a Location

Who is running the clinical trial?

Genesis Research LLCLead Sponsor

Media Library

Trans-perineal Focal Laser Ablation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05826470 — N/A
Prostate Cancer Research Study Groups: Laser Ablation
Prostate Cancer Clinical Trial 2023: Trans-perineal Focal Laser Ablation Highlights & Side Effects. Trial Name: NCT05826470 — N/A
Trans-perineal Focal Laser Ablation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05826470 — N/A
~6 spots leftby Oct 2025